Focused Ultrasound Therapy
Focused ultrasound is a therapeutic technology that could transform the quality of life and decrease the cost of care for patients with the pre-malignant disease of actinic keratosis. This novel technology focuses beams of ultrasound energy precisely and accurately on targets in the body without damaging surrounding normal tissue.
How it Works
Where the beams converge, focused ultrasound produces several therapeutic effects that are being evaluated. One is to use low intensity neuromodulation which can be aimed at various locations including the amygdala or the ventral striatum, with the goal of modulating the impact of stimulations to reduce anxiety. A second approach is to use high frequency energy to create a lesion in the anterior nucleus.
The primary options for treatment of anxiety include medication, but it is often limited in its success.
Advantages
For certain patients, focused ultrasound could provide a noninvasive alternative to surgery with less risk of complications – such as like surgical wound healing or infection – at a lower cost. Focused ultrasound can reach the desired target without damaging surrounding tissue, and it can be repeated, if necessary.
Clinical Trials
A clinical trial in California is using low frequency neuromodulation to treat anxiety.
A clinical trial in Texas is using low frequency neuromodulation to treat anxiety.
Another clinical trial in Texas is using low frequency neuromodulation to treat the combination of anxiety and obsessive compulsive disorder.
A clinical trial in Rhode Island is using low frequency neuromodulation to treat the combination of anxiety and depression.
A clinical trial is organizing in Virginia using low frequency neuromodulation to treat anxiety.
A clinical trial is organizing in Ohio that will use high frequency ablation to treat focal seizure propagation and anxiety.
See a full list of anxiety clinical trials.
Regulatory Approval and Reimbursement
Focused ultrasound treatment for anxiety is not yet approved by regulatory bodies or covered by medical insurance companies.
Notable Papers
Ziebell P, Rodrigues J, Forster A, Sanguinetti JL, Allen JJ, Hewig J. Inhibition of midfrontal theta with transcranial ultrasound explains greater approach versus withdrawal behavior in humans. Brain Stimul. 2023 Aug 21;16(5):1278-1288. doi: 10.1016/j.brs.2023.08.011. PMID: 37611659
Becker CR, Milad MR. Contemporary Approaches Toward Neuromodulation of Fear Extinction and Its Underlying Neural Circuits. Curr Top Behav Neurosci. 2023 Sep 2. doi: 10.1007/7854_2023_442. Online ahead of print. PMID: 37658219
Legon W, Strohman A, In A, Stebbins K, Payne B. Non-invasive neuromodulation of sub-regions of the human insula differentially affect pain processing and heart-rate variability. bioRxiv. 2023 May 5:2023.05.05.539593. doi: 10.1101/2023.05.05.539593. Preprint. PMID: 37205396
Chu PC, Huang CS, Ing SZ, Yu HY, Fisher RS, Liu HL. Pulsed Focused Ultrasound Reduces Hippocampal Volume Loss and Improves Behavioral Performance in the Kainic Acid Rat Model of Epilepsy. Neurotherapeutics. 2023 Mar;20(2):502-517. doi: 10.1007/s13311-023-01363-7. Epub 2023 Mar 14. PMID: 36917440
Zhang X, Xu W, Sang G, Yu D, Shi Q. A measure for perioperative anxiety symptoms in patients with FUAS – treated uterine fibroids: development and validation. Int J Hyperthermia. 2022;39(1):525-529. doi: 10.1080/02656736.2022.2051612.PMID: 35300541
